Results 21 to 30 of about 260,498 (362)

Proteochemometric modeling of HIV protease susceptibility

BMC Bioinformatics, 2008
Background A major obstacle in treatment of HIV is the ability of the virus to mutate rapidly into drug-resistant variants. A method for predicting the susceptibility of mutated HIV strains to antiviral agents would provide substantial clinical benefit ...
Prusis Peteris, Spjuth Ola, Eklund Martin, Lapins Maris, Wikberg Jarl ES   +4 more
doaj   +1 more source

The association between protease inhibitors and anal cancer outcomes in veterans living with HIV treated with definitive chemoradiation: a retrospective study

BMC Cancer, 2021
Background The incidence of anal squamous cell carcinoma has been increasing, particularly in people living with HIV (PLWH). There is concern that radiosensitizing drugs, such as protease inhibitors, commonly used in the management of HIV, may increase ...
Alison K. Yoder, David S. Lakomy, Yongquan Dong, Suchismita Raychaudhury, Kathryn Royse, Christine Hartman, Peter Richardson, Donna L. White, Jennifer R. Kramer, Lilie L. Lin, Elizabeth Chiao   +10 more
doaj   +1 more source

Accessory mutations balance the marginal stability of the HIV-1 protease in drug resistance

, 2020
The HIV-1 protease is a major target of inhibitor drugs in AIDS therapies. The therapies are impaired by mutations of the HIV-1 protease that can lead to resistance to protease inhibitors.
Hemmateenejad, B., Weikl, T.
core   +1 more source

Identification of drug resistance mutations in HIV from constraints on natural evolution [PDF]

, 2015
Human immunodeficiency virus (HIV) evolves with extraordinary rapidity. However, its evolution is constrained by interactions between mutations in its fitness landscape.
Barton, John P., Butler, Thomas C., Chakraborty, Arup K., Kardar, Mehran   +3 more
core   +2 more sources

Atazanavir and lopinavir profile in pregnant women with HIV: tolerability, activity and pregnancy outcomes in an observational national study [PDF]

, 2014
Background: Atazanavir and lopinavir represent the main HIV protease inhibitors recommended in pregnancy, but comparative data in pregnant women are limited. Methods: Women from a national observational study, exposed in pregnancy to either atazanavir or
. . . ]., Anna Degli Antoni, Anna Maria Marconi, Arsenio Spinillo, CAPRETTI, MARIA GRAZIA, Carmela Pinnetti, Daniela Francisci, Enrica Tamburrini, FALDELLA, GIACOMO, Giulia Masuelli, Giuseppina Liuzzi, Marco Floridia, Marina Ravizza, MARSICO, CONCETTA, Marta Fiscon, on behalf of The Italian Group on Surveillance on Antiretroviral Treatment in Pregnancy [. . ., Pasquale Martinelli, Vania Giacomet   +17 more
core   +1 more source

Sechs historische Grabsteine, um 1700, vom Alten Friedhof in Gießen [PDF]

, 1994
In this work, we applied a coarse-grained molecular dynamics method for simulating inhibitors entering the binding cavity of human immunodeficiency virus type 1 protease (HIV-1 PR).
Huang, Yonggang, Hwang, K. C., Ji, Baohua, Li, Dechang, Liu, Ming S.   +4 more
core   +1 more source

Higher Desolvation Energy Reduces Molecular Recognition in Multi-Drug Resistant HIV-1 Protease

Biology, 2012
Designing HIV-1 protease inhibitors that overcome drug-resistance is still a challenging task. In this study, four clinical isolates of multi-drug resistant HIV-1 proteases that exhibit resistance to all the US FDA-approved HIV-1 protease inhibitors and ...
Ladislau C. Kovari, Iulia A. Kovari, Joseph S. Brunzelle, Samuel J. Reiter, Zhigang Liu, Tamaria G. Dewdney, Yong Wang   +6 more
doaj   +1 more source

Inhibitors of SARS-CoV entry--identification using an internally-controlled dual envelope pseudovirion assay. [PDF]

, 2011
Severe acute respiratory syndrome-associated coronavirus (SARS-CoV) emerged as the causal agent of an endemic atypical pneumonia, infecting thousands of people worldwide.
Agudelo, Juliet, Amberg, Sean M, Chen, Yen Ting, Craik, Charles S, Goetz, David H, Hansell, Elizabeth, Lu, Kai, McKerrow, James, Roush, William R, Simmons, Graham, Zhou, Yanchen   +10 more
core   +1 more source

Molecular Basis for Drug Resistance in HIV-1 Protease

Viruses, 2010
HIV-1 protease is one of the major antiviral targets in the treatment of patients infected with HIV-1. The nine FDA approved HIV-1 protease inhibitors were developed with extensive use of structure-based drug design, thus the atomic details of how the ...
Celia A. Schiffer, Kelly Thayer, Ellen A. Nalivaika, Ayşegül Özen, Moses M. Prabu-Jeyabalan, Madhavi N.L. Nalam, Nancy M. King, Rajintha M. Bandaranayake, Jennifer F. Murzycki, Seema Mittal, Madhavi Kolli, Yufeng Cai, Akbar Ali   +12 more
doaj   +1 more source

Novel wild type and mutate HIV-1 protease inhibitors containing heteroaryl carboxamides in P2: Synthesis, biological evaluations and in silico ADME prediction

Results in Chemistry, 2023
The Virus HIV-1 infection still represents a serious disease even if actually it is transformed in chronic pathology. Considering the crucial role of the enzyme Protease in life cycle of HIV many efforts have been made in the research of new organic ...
Maria Francesca Armentano, Paolo Lupattelli, Faustino Bisaccia, Rosarita D'Orsi, Rocchina Miglionico, Ilaria Nigro, Alessandro Santarsiere, Federico Berti, Maria Funicello, Lucia Chiummiento   +9 more
doaj   +1 more source